Amended Statement of Ownership (sc 13g/a)
14 Febrero 2020 - 10:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE
13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*
ARCTURUS THERAPEUTICS HOLDINGS INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
03969T109
(CUSIP Number)
December 31, 2019
(Date of Event Which Requires Filing of
this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
x Rule
13d-1(b)
¨ Rule
13d-1(c)
¨ Rule
13d-1(d)
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
CUSIP No. 03969T109
|
13G
|
Page 2 of 5 Pages
|
1.
|
NAMES OF REPORTING PERSONS
|
|
|
ARK Investment Management LLC
|
|
|
|
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
|
|
(a)¨
|
|
|
(b)¨
|
|
|
3.
|
SEC USE ONLY
|
|
|
|
|
|
|
|
4.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
Delaware, United States
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
SOLE VOTING POWER
|
|
|
1,383,756
|
|
|
|
|
6.
|
SHARED VOTING POWER
|
|
|
0
|
|
|
|
|
7.
|
SOLE DISPOSITIVE POWER
|
|
|
1,383,756
|
|
|
|
|
8.
|
SHARED DISPOSITIVE POWER
|
|
|
0
|
|
|
|
|
9.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
1,383,756
|
|
|
|
|
10.
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
|
|
¨
|
|
|
|
|
11.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
9.14%
|
|
|
|
|
12.
|
TYPE OF REPORTING PERSON
|
|
|
IA
|
|
|
|
|
CUSIP No. 03969T109
|
13G
|
Page 3 of 5 Pages
|
Item 1(a) Name of issuer:
Arcturus Therapeutics Holdings Inc.
Item 1(b) Address of issuer's principal executive offices:
10628 Science Center Drive
San Diego, CA 92121
Item 2(a) Name of person filing:
ARK Investment Management LLC
Item 2(b) Address or principal business office or, if none,
residence:
ARK Investment Management LLC
3 East 28th Street, 7th Floor
New York, NY 10016
Item 2(c) Citizenship:
Delaware, United States
Item 2(d) Title of class of securities:
Common Stock
Item 2(e) CUSIP No.:
03969T109
Item
3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is
a:
(a) ¨ Broker
or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b) ¨ Bank as
defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) ¨ Insurance
company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d) ¨ Investment
company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
(e) x An investment
adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f) ¨ An employee
benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g) ¨ A parent
holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h) ¨ A savings
associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
CUSIP No. 03969T109
|
13G
|
Page 4 of 5 Pages
|
(i) ¨ A church
plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940
(15 U.S.C. 80a-3);
(j) ¨ A non-U.S.
institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k) ¨ Group,
in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: ____
Item 4. Ownership
|
(a)
|
Amount beneficially owned:
|
1,383,756
9.14%
|
(c)
|
Number of shares as to which such person has:
|
(i) Sole power to vote or to
direct the vote: 1,383,756
(ii) Shared power to vote or to direct
the vote: 0
(iii) Sole power to dispose or to direct
the disposition of: 1,383,756
(iv) Shared power to dispose or to
direct the disposition of: 0
Item 5. Ownership of 5 Percent or Less of a Class.
Not applicable.
Item
6. Ownership of More than 5 Percent on Behalf of Another Person.
Not applicable.
Item
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
or Control Person.
Not applicable.
Item
8. Identification and Classification of Members of the Group.
Not applicable.
Item
9. Notice of Dissolution of Group.
Not applicable.
CUSIP No. 03969T109
|
13G
|
Page 5 of 5 Pages
|
Item
10. Certifications.
By signing below I certify that, to the
best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business
and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer
of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that
purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
The reporting persons agree that this statement
is filed on behalf of each of them.
Dated: February 14, 2020
|
ARK Investment Management LLC
|
|
|
|
|
|
|
By:
|
/s/ Kellen Carter
|
|
|
|
Name: Kellen Carter
|
|
|
|
Title: Chief Compliance Officer
|
|
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024